Salute e Benessere

New two-year follow-up of Roche's Columvi extends overall survival in relapsed…

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are not candidates for transplant 1 89% of patients whose cancer had fully responded at the end of treatment with Columvi in combination with chemotherapy were still alive and 82% showed no signs of cancer one year post-treatment 1 Timely initiation of effective therapy at relapse or after...
Nasdaq GlobeNewswire
23/05/2025

MindHYVE.ai™ and Islamabad Diagnostic Centre Forge Strategic Alliance to Launch…

"This isn't just AI—it's agentic intelligence in action," said Belal Faruki, Founder & CEO of MindHYVE.ai™. "By fusing swarm intelligence with domain-specific reasoning models, we're equipping clinicians with AI collaborators that learn, adapt, and elevate patient outcomes—ethically and transparently." "This isn't just AI—it's agentic intelligence in action," saidBelal Faruki, Founder & CEO of MindHYVE.ai™. "By fusing swarm intelligence with…
PR Newswire
23/05/2025

Inclusive Design Gains Momentum as Canton Fair Spotlights Senior-Friendly…

Aging-focused innovation also featured prominently in the Canton Fair's first-ever Service Robots Zone. Zhejiang Fubao Intelligent Technology Co., Ltd. showcased an advanced companion robot built for elderly care. Equipped with AI-powered health monitoring, real-time physiological tracking, and telemedicine capabilities, the robot offers features such as blood oxygen detection, medication reminders, and emergency alert systems, all essential for seniors living independently. Aging-focused...
PR Newswire
23/05/2025

Johnson & Johnson's IMAAVY Gets FDA Approval, Taking on Top Players in…

According to DelveInsight's analysis, there were approximately 300,000 diagnosed prevalent cases of myasthenia gravis across the 7MM in 2024. This number is expected to grow steadily over the forecast period (2025–2034), with a projected CAGR. According to DelveInsight's analysis, there were approximately300,000diagnosed prevalent cases of myasthenia gravis across the 7MM in 2024. This number is expected to grow steadily over the forecast period (2025–2034), with a projected CAGR. The...
PR Newswire
22/05/2025

ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic…

Currently, there is no cure for DEB. Management is primarily supportive, focusing on wound care, controlling pain and itching, preventing infections, providing nutritional assistance, and addressing complications that may arise. Currently, there is no cure for DEB. Management is primarily supportive, focusing on wound care, controlling pain and itching, preventing infections, providing nutritional assistance, and addressing complications that may arise. Learn more about the DEB therapeutic...
PR Newswire
22/05/2025

Boehringer Ingelheim to present early clinical evidence of innate immune…

· BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). · Next generation SIRPα inhibitor BI 770371 was shown to be well tolerated alone and in combination with PD1 inhibitor ezabenlimab in a dose...
Nasdaq GlobeNewswire
22/05/2025

Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the…

Media ReleaseCOPENHAGEN, Denmark; May 22, 2025 First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S ® ) in patients with recurrent/advanced endometrial cancer Presentation of long-term follow-up data from analysis of Phase 1/2 EPCORE™ NHL-1 study of epcoritamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)Genmab A/S (Nasdaq:GMAB)announced today that it will present new...
Nasdaq GlobeNewswire
22/05/2025

Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional…

Novel TROP2-targeting AVC-Booster demonstrated prolonged and significantly improved tumor control in animal models, and activation of the full immune system in non-small cell lung cancer patient samples Avidicure's first-in-class dual agonistic multifunctional AVC-Boosters are designed to harness the full power of the immune system, and are avidity engineered to specifically and safely target only cancer cells. AVC-S-101 has shown prolonged and significantly improved tumor control in mice...
Nasdaq GlobeNewswire
22/05/2025

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at…

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodiesLong-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at ASCO and highlight its potential to transform the treatment landscape for first-line HER2-positive gastroesophageal cancerZW171 Trial-in-Progress (TiP) poster at ASCO, ZW191 TiP poster at ESMO Gynaecological Cancers Congress; trial...
Nasdaq GlobeNewswire
22/05/2025

GENFIT Reports First Quarter 2025 Financial Information

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), May 22, 2025-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its cash position as of March 31, 2025 and revenues for the first three months of 2025. 1Cash position As of March 31, 2025, the Company's cash and cash equivalents amounted to €129.5 million compared with €74...
Nasdaq GlobeNewswire
22/05/2025

Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer…

Teva ”) announced today that it is increasing the maximum tender amount of its tender offer previously announced on May 19, 2025 from $2.0 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) to approximately $2.25 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) (the “ Total Maximum Amount ”).Teva is also increasing the Pool Tender Caps applicable to the Pool 2 Notes and the Pool 3 Notes (each, as defined...
Nasdaq GlobeNewswire
22/05/2025

Are you getting enough B12? Nature's Best reveals why 'normal' might not be…

Results showed that those with lower B12 levels, though still within the standard normal range, exhibited slower cognitive and visual processing speeds. Results showed that those with lower B12 levels, though still within the standard normal range, exhibited slower cognitive and visual processing speeds. Additionally, these individuals had more white matter lesions on the brain, which are associated with dementia and stroke risk. Furtherresearchhas revealed that B12, when combined...
PR Newswire
22/05/2025

Press release: Sequana Medical announces results of Annual and Extraordinary…

Sequana Medical announces results of Annual and Extraordinary General Meetings of Shareholders Ghent, Belgium, 22 May 2025 – Sequana Medical NV(Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that all proposed resolutions submitted to the Annual and Extraordinary General Meetings of Shareholders were approved at the meetings held today at…
Nasdaq GlobeNewswire
22/05/2025

Oxurion Announces Results on the Annual Shareholders' Meeting of 13 May 2025

Leuven, BELGIUM – May 22, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders' meeting on May 13, 2025. The shareholders approved all items on the agenda of the annual shareholders' meeting. All documents pertaining to the annual shareholders' meeting held on…
Actusnews Wire
22/05/2025

FDA approves Roche's Susvimo for diabetic retinopathy

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine monthsSusvimo's innovative technology via the Port Delivery Platform may offer an alternative to regular eye injections in the USDiabetic retinopathy affects almost 10 million people in the US and is the third FDA-approved indication for Susvimo, which is also approved for treating neovascular or 'wet' age-related macular...
Nasdaq GlobeNewswire
22/05/2025

Cellenkos Inc. and King Faisal Specialist Hospital & Research Centre, Sign…

"At KFSHRC, we remain deeply committed to improving treatment options for patients with Aplastic Anemia and GVHD—conditions that present serious challenges for many individuals and families in our care. We look forward to working together with Cellenkos in a way that serves our patients and supports the advancement of tailored therapeutic solutions," said His Excellency Dr. Majid bin Ibrahim Al Fayyadh, CEO of KFSHRC. "We are thrilled about this partnership and opportunity to work…
PR Newswire
22/05/2025

Neurostimulation Devices Market to Reach USD 17.2 Billion by 2031 - Driven by…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-27V15737/Global_and_India_Neurostimulation_Devices_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-27V15737/Global_and_India_Neurostimulation_Devices_Market Major Factors Driving the Growth of Neurostimulation Devices Market: The neurostimulation devices market is witnessing robust growth due to rising cases of neurological disorders, chronic pain, and...
PR Newswire
22/05/2025

Human Leukocyte Antigen (HLA) Typing for Transplant Market worth US$1.4 billion…

Browse in-depth TOC on "HLA Typing for Transplant Market" Browse in-depth TOC on "HLA Typing for Transplant Market" 250 - Tables 50 - Figures 350 - Pages By Based on product & service,the HLA typing market for transplants is categorized into three segments: software & services, reagents &consumables, and instruments. In 2024, the reagents & consumables segment led in global market share; this growing prominence is primarily driven by a rising demand for...
PR Newswire
22/05/2025

BDMS Wellness Clinic, Led by Dr. Tanupol Virunhagarun, Strengthens Wellness Ties…

In a significant diplomatic and health initiative, Dr. Tanupol Virunhagarun, known as "Dr. Amp," represented Thailand at a seminar held at the Royal Thai Embassy in Riyadh, Kingdom of Saudi Arabia. The seminar, titled "Wellness Hub Thailand: The Future of Global Wellness," was organized to promote Thailand's vision of becoming a global leader in preventive healthcare and wellness tourism. In a significant diplomatic and health initiative, Dr. Tanupol Virunhagarun, known as…
PR Newswire
22/05/2025

Vistin Pharma ASA: Minutes from the annual general meeting 2025

Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 22 May 2025. For further information, please contact:Alexander Karlsen CFO +47 97 05 36 21 [email protected] information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.Attachment Minutes OGM Vistin Pharma ASA_22 May 2025
Nasdaq GlobeNewswire
22/05/2025

Evaxion doses first patient in extension of phase 2 trial exploring the full…

Generation of additional clinical data allows for a more comprehensive assessment of the full potential of EVX-01, while strengthening the already strong clinical data packageWill provide insights into the durability of immune and clinical responses up to three yearsExtension phase enables exploration of EVX-01 as monotherapy, following initial combination with standard of careMinimal costs are associated with the extension as clinical sites are already running and the vaccines...
Nasdaq GlobeNewswire
22/05/2025

Description of the Share Repurchase Program Covered by the Liquidity Agreement…

Daix, May 22, 2025Pursuant to Article 241-2 of the AMF General Regulations ( Règlement Général de l'Autorité des marchés financiers ), the purpose of this description is to present the objectives and terms of the Company's share repurchase program approved by the Ordinary General Meeting of May 22, 2025, it being specified that the Company does not to date intend to pursue any objective other than to animate the market under a liquidity agreement which has been in place since the listing...
Nasdaq GlobeNewswire
22/05/2025

Amphista Therapeutics showcases cryo-EM enabled platform for discovering novel…

Innovative Eclipsys® platform enables rational design of novel Targeted Glues™ with superior drug-like properties Cambridge, UK, 22 May 2025– Amphista Therapeutics, a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, has today presented the Company's unique approach to constructing novel, orally bioavailable Targeted Glue™ protein degraders with mechanisms of action (MoA) distinct from traditional CRBN/VHL approaches using its proprietary...
Nasdaq GlobeNewswire
22/05/2025

Purina Institute Global Summit on Future of Veterinary Care Now Available…

With over 5,500 veterinary professionals registered, the event underscored the global veterinary community's commitment to innovation and excellence and the emphasis the Purina Institute places on science to improve pets' lives. With over 5,500 veterinary professionals registered, the event underscored the global veterinary community's commitment to innovation and excellence and the emphasis the Purina Institute places on science to improve pets' lives. "At the Purina Institute, we…
PR Newswire
22/05/2025
Altri  Comunicati